Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood transfusions after ICU: a new hope for tired survivors?

NCT ID NCT04591574

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving blood transfusions to patients who are anemic after leaving the intensive care unit (ICU) can help them feel less tired and recover better. About 346 adults from UK hospitals will be randomly assigned to either the usual care (transfusions only if very needed) or a more active transfusion plan. The goal is to see if treating anemia more aggressively improves quality of life and physical function over six months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

346 people

The number who actually took part.

Started

Sep 2020

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient who received level 3 ICU care at any time point during the current hospital admission (defined as advance respiratory support and/or at least two organ support). * Patient considered ready for discharge from ICU by the caring clinical team. * Hb less than or equal to 94g/L when ready for ICU discharge or during the first seven days following the decision by the treating clinician that the patient is ready for ICU discharge. * 16years of age or older * Patient expected to remain in study hospital until hospital discharge. * Consent provided (by participant or in accordance with appropriate mental capacity legislation for the site). Exclusion Criteria: * Contraindication or objection to RBC transfusion * Active bleeding when screened * Primary neurological ICU admission diagnosis * Patients discharged from the ICU following cardiac surgery * Currently receiving or planned to receive end-of-life care * Not expected by clinical team to survive to hospital discharge * Patient with a proven chronic haematological disease that requires regular RBC transfusion to treat anaemia * Patient with dialysis-dependent chronic renal failure prior to ICU admission * Patient receiving regular erythropoietin (or any erythropoiesis stimulating agent) treatment for anaemia prior to ICU admission * Unable to obtain consent (frompatietn or in accordance with appropriate mental capacity legislation for the site) * Readmission to ICU during current hospitalisation episode and not enrolled following previous ICU admissions * Patient recovering following liver transplantation, kidney transplantation, or combined kidney/pancreas transplantation * Patient recovering from variceal bleeding due to chronic liver disease * Prisoners * Patient due for imminent hospital discharge within the next 24 hours

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anemia acute are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anemia Fatigue

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • NHS Lothian

    Edinburgh, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.